Dr. Akhil Srivastava

Dr. Srivastava leads projects studying the molecular basis of cancer pathophysiology and developing novel anti-cancer therapeutic strategies focusing on Extracellular Vesicles (EVs) or ‘exosomes.’ The area of interest includes elucidating the function of cancer cell-derived EVs in creating a favorable ecosystem for establishing a cancer lesion site, modulating the immune system, and developing resistance to therapies. He is also interested in studying the molecular composition of EVs to decipher stringent molecular signals that can be used to develop Artificial Intelligence (AI) tools for high-precision cancer diagnosis and treatment prediction. In addition, to leverage the translational potential of EVs, Dr. Srivastava has engineered EVs as a novel biomimetic multifunctional theranostic system for the simultaneous tumor-targeted delivery of anti-cancer therapeutics and imaging.